In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $70.01, marking a +1.71% move from the previous day. This change outpaced the S&P 500's 0.57% gain on the day. Meanwhile, the Dow Jones lost 0.14% and the Nasdaq, a tech-heavy index, added 1.25%.
Prior to today's trading, shares of the company had gained 6.15% over the past month. This has outpaced the Medical sector's gain of 2.05% and the S&P 500's gain of 5.07% in that time.
Analysts and investors alike will be closely monitoring CRISPR Therapeutics AG's performance in its upcoming earnings release. The company is expected to post an EPS of -$0.21, which is an increase of 85.11% compared to the same quarter last year. At the same time, our latest consensus estimate is projecting revenue of $144.28 million, reflecting an increase of 1442670% from the equivalent quarter last year.
Investors should also pay attention to the latest changes to analyst estimates for CRISPR Therapeutics AG. These latter adjustments often reflect the changing dynamics of short-term trading patterns. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research suggests these estimate changes have a direct relationship with the upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model that takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has a remarkable, outside-audited track record of outperformance, with #1 stocks returning an average annual gain of + 25% since 1988. The Zacks Consensus EPS estimate has moved 0.06% higher over the past month. CRISPR Therapeutics AG currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 103, putting it in the top 41% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% of industries outperform the bottom half by a factor of 2 to 1.
Remember to use Zacks.com to follow these and more stock-moving metrics over the coming trading sessions.
Want the latest recommendations from Zacks Investment Research? Today you can download the 7 best stocks for the next 30 days. Click to get this free report
CRISPR Therapeutics AG (CRSP): Free Stock Analysis Report
To read this article on Zacks.com, click here.
